Dr Elias Mai speaks to ecancer about a study he presented at ASH 2024 on the impact of minimal residual disease on progression-free survival in patients with newly diagnosed multiple myeloma treated with isatuximab, lenalidomide, bortezomib and dexamethasone induction therapy.

He explains that at the current data cut-off the rate of MRD negativity in both arms increased post-transplant with a greater increase in patients who received isatuximab-RVd as induction therapy compared to RVd alone.

Dr Mai also highlights that the isatuximab-RVd arm reduced the risk of progression or death by 30% compared to the RVd arm.